We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Read MoreHide Full Article
Ionis Pharmaceuticals (IONS - Free Report) reported $452 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 100.9%. EPS of $0.86 for the same period compares to -$0.45 a year ago.
The reported revenue represents a surprise of +66.96% over the Zacks Consensus Estimate of $270.73 million. With the consensus EPS estimate being $0.27, the EPS surprise was +218.52%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Total research and development revenue: $349 million versus $183.06 million estimated by 10 analysts on average.
Revenue- Total commercial revenue: $103 million versus the 10-analyst average estimate of $87.57 million. The reported number represents a year-over-year change of +43.1%.
Revenue- Commercial revenue- SPINRAZA royalties: $54 million compared to the $55.23 million average estimate based on nine analysts.
Revenue- Commercial revenue- WAINUA royalties: $10 million versus $11.11 million estimated by nine analysts on average.
Revenue- Commercial revenue- Other commercial revenue- TEGSEDI and WAYLIVRA revenue, net: $14 million versus $9.78 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +75% change.
Commercial revenue-Royalty revenue-Other royalties: $6 million versus the eight-analyst average estimate of $5.86 million.
Revenue- Research and development revenue- Collaborative agreement revenue: $337 million versus the eight-analyst average estimate of $187.02 million. The reported number represents a year-over-year change of +139%.
Shares of Ionis Pharmaceuticals have returned +3.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Ionis Pharmaceuticals (IONS - Free Report) reported $452 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 100.9%. EPS of $0.86 for the same period compares to -$0.45 a year ago.
The reported revenue represents a surprise of +66.96% over the Zacks Consensus Estimate of $270.73 million. With the consensus EPS estimate being $0.27, the EPS surprise was +218.52%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Ionis Pharmaceuticals here>>>
Shares of Ionis Pharmaceuticals have returned +3.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.